Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, January 9, 2018
Biogen and Eisai Commence Co-Promotion of Multiple Sclerosis Treatments in Japan
Eisai and Merck & Co. Receive Breakthrough Therapy Designation from U.S. FDA for LENVIMA and KEYTRUDA
Wednesday, December 27, 2017
Eisai: Anticancer Agent Lenvatinib Designated for Priority Review and Approval by CFDA for Hepatocellular Carcinoma
Friday, December 22, 2017
Eisai: Adaptive Phase II Study of BAN2401 In Early Alzheimer's Disease Continues Toward 18-Month Endpoint
Monday, December 18, 2017
Eisai Launches Educational Materials for Understanding Dementia
Wednesday, December 13, 2017
Eisai's Aricept Approved for Additional Indication of Severe Alzheimer's Disease in China
Friday, December 8, 2017
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen
Wednesday, December 6, 2017
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan
Thursday, November 30, 2017
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China
Friday, November 24, 2017
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: